Reduction of immunosuppression for transplant-associated skin cancer: Expert consensus survey

British Journal of Dermatology

Volumn 154, Issue 3, 2006, Pages 395-400

  Otley, C C ^a   Berg, D ^b   Ulrich, C ^c   Stasko, T ^d   Murphy, G M ^e   Salasche, S J ^f   Christenson, L J ^a   Sengelmann, R ^g   Loss Jr , G E ^h   Garces, J ^h  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d VANDERBILT UNIVERSITY   (United States)

^e BEAUMONT HOSPITAL   (Ireland)

^f UNIVERSITY OF ARIZONA   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Consensus guidelines; Immunosuppression; Skin cancer; Squamous cell carcinoma; Therapy; Transplant

Indexed keywords

CONSENSUS; DISEASE ASSOCIATION; DISEASE SEVERITY; EXPERT SYSTEM; GRAFT RECIPIENT; HEALTH SURVEY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REDUCTION; REVIEW; SKIN CANCER;

DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; SKIN NEOPLASMS;

EID: 33644899100     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.07087.x     Document Type: Review

References (39)

1. Berg D Otley CC Skin cancer in organ transplant recipients. epidemiology, pathogenesis, and management J Am Acad Dermatol 2002 47 1 17
2. Euvrard S Kanitakis J Claudy A Skin cancers after organ transplantation N Engl J Med 2003 348 1681 91
3. Martinez JC Otley CC Stasko T et al. Transplant-Skin Cancer Collaborative. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study Arch Dermatol 2003 139 301 6
4. Veness MJ Quinn DI, Ong CS et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience Cancer 1999 85 1758 64
5. Sheil AG Disney AP Mathew TH Amiss N De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation Transplant Proc 1993 25 1383 4
6. Ong CS Keogh AM Kossard S et al. Skin cancer in Australian heart transplant recipients J Am Acad Dermatol 1999 40 27 34
7. Bavinck JN Tieben LM van der Woude FJ et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study J Clin Oncol 1995 13 1933 8
8. Euvrard S Kanitakis J Bosshard S et al. No recurrence of posttransplantation Kaposi's sarcoma three years after renal retransplantation Transplantation 2002 73 297 9
9. Penn I Kaposi's sarcoma in transplant recipients Transplantation 1997 64 669 73
10. Penn I Sarcomas in organ allograft recipients Transplantation 1995 60 1485 91
11. Woodle ES Hanaway M Buell J et al. Israel Penn International Transplant Tumor Registry. Kaposi sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Tumor Registry Transplant Proc 2001 33 3660 1
12. Besnard V Euvrard S Kanitakis J et al. Kaposi's sarcoma after liver transplantation Dermatology 1996 193 100 4
13. Duman S Toz H Asci G et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression Nephrol Dial Transplant 2002 17 892 6
14. Green M Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation Am J Transplant 2001 1 103 8
15. Starzl TE Nalesnik MA Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy Lancet 1984 1 583 7
16. Mozzanica N Cattaneo A Fracchiolla N et al. Posttransplantation cutaneous B-cell lymphoma with monoclonal Epstein-Barr virus infection, responding to acyclovir and reduction in immunosuppression J Heart Lung Transplant 1997 16 964 8
17. Hanto DW Frizzera G Gajl-Peczalska KJ et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation N Engl J Med 1982 306 913 18
18. Armitage JM Kormos RL Stuart RS et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression J Heart Lung Transplant 1991 10 877 86
19. Tsai DE Hardy CL Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients Transplantation 2001 71 1076 88
20. Soulillou JP Giral M Controlling the incidence of infection and malignancy by modifying immunosuppression Transplantation 2001 72 Suppl. 12 S89 93
21. Dantal J Hourmant M Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens Lancet 1998 351 623 8
22. Otley CC Coldiron BM Stasko T Goldman GD Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants Arch Dermatol 2001 137 459 63
23. Moloney FJ Kelly PO Kay EW et al. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma Dermatol Surg 2004 30 674 8
24. Jensen P Hansen S Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens J Am Acad Dermatol 1999 40 177 86
25. Glover MT Deeks JJ Raftery MJ et al. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients Lancet 1997 349 398
26. Kehinde EO Petermann A Morgan JD et al. Triple therapy and incidence of de novo cancer in renal transplant recipients Br J Surg 1994 81 985 6
27. Shuttleworth D Marks R Griffin PJ Salaman JR Epidermal dysplasia and cyclosporine therapy in renal transplant patients: a comparison with azathioprine Br J Dermatol 1989 120 551 4
28. Hiesse C Rieu P Kriaa F et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1,700 patients followed during a 25-year period Transplant Proc 1997 29 831 3
29. Ramsay HM Fryer AA Reece S et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients Am J Kidney Dis 2000 36 167 76
30. Fortina AB Caforio AL Piaserico S et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis J Heart Lung Transplant 2000 19 249 55
31. Gjersvik P Hansen S Moller B et al. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients? Transpl Int 2000 13 Suppl. 1 S380 1
32. Otley CC Maragh SL Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy Dermatol Surg 2005 31 163 8
33. Kirk AD Mannon RB Swanson SJ Hale DA Strategies for minimizing immunosuppression in kidney transplantation Transpl Int 2005 18 2 14
34. Balch CM Soong SJ Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 2001 19 3622 34
35. Penn I Malignant melanoma in organ allograft recipients Transplantation 1996 61 274 8
36. Rowe DE Carroll RJ Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection J Am Acad Dermatol 1992 26 976 90
37. Kahan BD Knight R Schoenberg L et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience Transplant Proc 2003 35 Suppl. S25 34
38. Mathew T Kreis H Friend P Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies Clin Transplant 2004 18 446 9
39. Kauffman HM Cherikh WS Cheng Y et al. Maintenance immunosuppression with mTOR inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 2005 80 883 9